Inmune Bio Inc. (INMB)
Market Closed
16 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary $
1. 57
-0.08
-4.8485%
$
50.25M Market Cap
- P/E Ratio
- Div Yield
196,200 Volume
-2.19 Eps
$ 1.65
Previous Close 
Want to track INMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but continues to make progress with a potential transformative data readout by spring 2024.
Seekingalpha | 2 years ago
2026 © Marketlog. All Rights Reserved.
